{
    "clinical_study": {
        "@rank": "124377", 
        "arm_group": {
            "arm_group_label": "Single", 
            "arm_group_type": "Experimental", 
            "description": "I-124-CLR1404, open-label"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to determine the optimal dose and imaging time\n      point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used\n      in future trials."
        }, 
        "brief_title": "Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  newly diagnosed glioblastoma or recurrent/suspected recurrent glioblastoma\n\n          -  scheduled to undergo a clinically-indicated surgery or biopsy (specific cohorts)\n\n          -  ECOG performance status of 0 to 2 (Appendix C)\n\n          -  18 years of age or older\n\n          -  has the initiative and means to be compliant with the protocol and be within\n             geographical proximity to make the required study visits\n\n          -  has the ability to read, understand and provide written informed consent for the\n             initiation of any study related procedures (or legal representative)\n\n          -  if female of childbearing potential must have a negative pregnancy test within 24\n             hours of enrollment\n\n          -  Women of childbearing potential and men who are able to father a child, must agree to\n             use an effective method of contraception (e.g., oral contraceptives, double-barrier\n             methods such as a condom and a diaphragm, intrauterine device, Norplant,\n             Depo-Provera) during the study and for 45 days following the last dose of the study\n             drug.\n\n        Exclusion Criteria:\n\n          -  ongoing grade 2 or greater toxicities due to previous therapies. However, tolerable\n             grade 2 adverse (e.g. neuropathy) events may be allowed at the discretion of the\n             investigator.\n\n          -  has following laboratory abnormalities\n\n               -  Platelets < 100,000/\u03bcL\n\n               -  WBC < 3000/\u03bcL\n\n               -  Hematocrit < 22%\n\n               -  Serum creatinine > 2.5 mg/dL\n\n               -  ALT > 1.5 x ULN\n\n               -  Bilirubin > 1.5 x ULN\n\n          -  ongoing chronic immunosuppressive therapy\n\n          -  history of hypersensitivity to iodine\n\n          -  any other concomitant serious illness or organ system dysfunction which in the\n             opinion of the investigator would either compromise subject safety or interfere with\n             the evaluation of the safety of the test drug\n\n          -  women of childbearing potential, or men who are able to father a child, unwilling to\n             use a medically acceptable method of contraception during the trial\n\n          -  pregnancy or breast-feeding\n\n          -  inability to comply with the protocol\n\n          -  use of any investigational drug within 4 weeks of dosing (unless a longer time period\n             is required by local regulations or the investigational agent)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898273", 
            "org_study_id": "DCL-13-002"
        }, 
        "intervention": {
            "arm_group_label": "Single", 
            "description": "single-dose, intravenous", 
            "intervention_name": "I-124-CLR1404", 
            "intervention_type": "Drug", 
            "other_name": "I-124-NM404"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glioma", 
            "Glioblastoma Multiforme", 
            "PET", 
            "Imaging", 
            "Radiopharmaceutical", 
            "Diagnostic"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "contact": {
                    "email": "aching@coh.org", 
                    "last_name": "Alexandra Ching", 
                    "phone": "626-471-9393"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Jana Portnow, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Tom Werner", 
                    "phone": "215-662-3060"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Hospital of University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Abass Alavi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "UW Cancer Connect", 
                    "phone": "800-622-8922"
                }, 
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin"
                }, 
                "investigator": {
                    "last_name": "John Kuo, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma", 
        "overall_official": [
            {
                "affiliation": "University of Wisconsin, Madison", 
                "last_name": "John Kuo, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Beckman Research Institute", 
                "last_name": "Jana Portnow, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Pennsylvania", 
                "last_name": "Abass Alavi, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Up to two dose levels (5 mCi and 7.5 mCi) will be evaluated in conjunction with multiple imaging time points to determine the optimal parameters for PET/CT brain imaging. Dosing will begin at 5 mCi and if the images are deemed inadequate, as assessed by count statistics and image quality, the 7.5 mCi dose level will be evaluated.", 
            "measure": "Optimal Imaging Parameters - Dose", 
            "safety_issue": "No", 
            "time_frame": "8 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898273"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Multiple imaging time points (Day 2, Day 3, and Day 4-8) will be evaluated to determine the optimal parameters for PET/CT brain imaging.", 
            "measure": "Optimal Imaging Parameters - Imaging Time Point", 
            "safety_issue": "No", 
            "time_frame": "8 days"
        }, 
        "source": "Cellectar Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cellectar Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}